Abstract: The method for distinguishing between prostate carcinoma and benign prostatic hyperplasia comprising: bringing an analyte sample containing a prostate-specific antigen (PSA) into contact with a carrier having an anti-free PSA antibody immobilized thereon, thereby binding free PSA to the anti-free PSA antibody immobilized on the carrier; thereafter bringing the carrier in which the free PSA is bound to the immobilized anti-free PSA antibody into contact with a monoclonal antibody capable of specifically recognizing a glycan in which a terminal sialic acid residue is bound to galactose through an ?(2,3) bond, thereby binding the monoclonal antibody recognizing the glycan to the free PSA bound to the anti-free PSA antibody; measuring the amount of the free PSA having an N-type glycan in which a terminal sialic acid residue is bound to galactose through an ?(2,3) bond; comparing the measured amount thus obtained with a preset cutoff value for prostate carcinoma and benign prostatic hyperplasia, thereby determinin

Abstract: An object of the present invention is to provide a method for distinguishing between prostate carcinoma and benign prostatic hyperplasia with high sensitivity and good reproducibility using a small amount of an analyte sample.

Abstract: A polymer containing an N-linked sialo-glycan wherein a sialo-glycan is condensed to a ?-polyglutamic acid using a chemical compound having an amino group on one end and a carboxyl group on another end and represented by the structural formula (I). Formula (I) (In the formula, Z means a hydroxy group or a residue represented by the formula (II), and n represents an integer of 10 or more, with the proviso that any one or more of the Z's is represented by the formula in (II).) Formula (II) (In the formula, X means a hydroxy group or an acetylamino group, Y1 and Y2 mean a hydroxyl group or an N-acetylneuraminic acid residue, L means a hydrocarbon, an m represents 0 or an integer of 1 or 2, with the proviso that Y1 and Y2 are not the same.

Abstract: A polymer containing an N-linked sialo-glycan wherein a sialo-glycan is condensed to a ?-polyglutamic acid using a chemical compound having an amino group on one end and a carboxyl group on another end and represented by the structural formula (I). Formula (I) (In the formula, Z means a hydroxy group or a residue represented by the formula (II), and n represents an integer of 10 or more, with the proviso that any one or more of the Z's is represented by the formula in (II).) Formula (II) (In the formula, X means a hydroxy group or an acetylamino group, Y1 and Y2 mean a hydroxyl group or an N-acetylneuraminic acid residue, L means a hydrocarbon, an m represents 0 or an integer of 1 or 2, with the proviso that Y1 and Y2 are not the same.

Abstract: A method in which the recognition specificity of a virus for a receptor sugar chain can be easily determined with a simple instrument or apparatus is provided. In a method for determining the recognition specificity of a virus for a receptor sugar chain or for determining the change in a host infected in accordance with the mutation of virus comprising, a sample of the virus is brought into contact with a support having a polymer with sialo-oligosaccharide immobilized on the surface thereof; and the degree of binding therein is assayed to determine the recognition specificity of said virus for said receptor sugar chain and to determine the change in a host range. The method is suitable for the surveillance of virus.

Abstract: A dengue virus infection inhibitor, as a drug effectively inhibiting the infection with dengue virus, which is characterized by containing, as the active ingredient, at least a carbohydrate molecule having as an essential constituent an oligosaccharide chain represented by the following formula (I): Hex1NAc?1-3Hex2?1-4Hex1?1- (I) (wherein Hex1 and Hex2 represent a hexose) is provided.

Abstract: A novel branched sialo-sugar molecule represented by the following formula (I) which is a substance which responds to a variation in the host range of an influenza virus or a variation in antigenicity and is useful as a drug or an adsorbent in a virus removal filter or the like capable of preventing the infection with a type A influenza virus and a type B influenza virus originating in any animals including humans: (wherein NeuAc represents N-acetylneuraminic acid in which the hydroxyl group, the carboxyl group and the amido group may be chemically modified with a halogen group, an alkyl group or an acyl group, either the same group or separate groups, Hex represents hexose, HexNAc represents N-acetylhexosamine and R represents a substrate selected from among a hydrogen atom, a hydrocarbon chain, a sugar chain, a lipid, a protein and a synthetic polymer, R may have a substituent, and the linkage between N-acetylneuraminic acid and hexose may be either an O-glycoside linkage occurring in nature or a chemic